© 2020 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
CAR T-Cell Therapy
FDA’s Fast Track Designation Granted to Allogeneic CAR Therapy for B-cell Precursor Acute Lymphoblastic Leukemia
August 19, 2020
The FDA has granted a fast track designation to PBCAR0191, a CD19-directed allogeneic chimeric antigen receptor T-cell therapy, for the treatment of patients with advanced B-cell precursor acute lymphoblastic leukemia.
Humanized CD19 CAR T-Cell Therapy Shows Early Promise as Treatment of Hematologic Malignancies
August 18, 2020
An investigator-initiated trial of a humanized CD19-directed chimeric antigen receptor T-cell therapy has been completed, demonstrating the therapy may be a safe and effective treatment for patients with hematologic malignancies.
Ibrutinib May Improve CAR T-Cell Production for Patients With Chronic Lymphocytic Leukemia
August 17, 2020
Ibrutinib during CAR T-cell culture improved the yield and function of CAR T-cell products as treatment of patients with chronic lymphocytic leukemia.
Autologous CAR T-Cell Therapy Induces Durable Responses in Relapsed/Refractory Hodgkin Lymphoma
August 06, 2020
"These data are significant, as they demonstrate that CAR T-cell therapy may be a safe and effective treatment option for patients with Hodgkin lymphoma and potentially other lymphomas expressing the CD30 antigen."
Tisagenlecleucel Demonstrates Favorable Complete Response Rate, Meets Phase II Primary End Point
August 04, 2020
Tisagenlecleucel, a chimeric antigen receptor T-cell therapy, showed evidence of clinical benefit for patients with relapsed or refractory follicular lymphoma, in terms of complete response rate, meeting the primary end point of the phase 2 ELARA clinical trial.
Axi-Cel Retains Its Benefit in a Real-World Setting in Large B-Cell Lymphomas
July 31, 2020
Axicabtagene ciloleucel demonstrated a similar overall response rate in both the trial and non-trial settings as treatment of patients with relapsed or refractory large B-cell lymphoma.
CAR T-Cell Therapy Evolves in Leukemia Treatment Landscape
July 13, 2020
Jae H. Park, MD, discusses the role of chimeric antigen receptor T-cell therapy in leukemias and how he sees this treatment evolving in the coming years.
CAR T Cell Agents Show Variance in Different Lymphoma Subtypes
July 08, 2020
Chimeric antigen receptor T-cell therapy when administered to patients with non-follicular low-grade lymphoma may experience different efficacy outcomes than patients with aggressive B-cell lymphomas, according to a single-institution retrospective data.
FDA Places Clinical Hold on MELANI-01 Trial for CAR T-Cell Therapy
July 07, 2020
The FDA has placed a clinical hold on the MELANI-01 clinical trial evaluating UCARTCS1A, a chimeric antigen receptor T-cell therapy.
Multidrug Combinations and CAR T-Cell Therapies for Heavily Pretreated Multiple Myeloma Shine at ASCO
July 07, 2020
Breakthrough data for systemic therapies in the treatment of various hematologic malignancies impressed attendees at the American Society of Clinical Oncology 2020 Virtual Scientific Program.